Filing Flows › Tenaya Therapeutics (TNYA) › R&D spending
Tenaya Therapeutics (TNYA) R&D spending by quarter
Tenaya Therapeutics' R&D spending was $14.9M in Q3 2026 (third quarter 2026), -10% from Q2 2026. Over the last 3 quarters it ranged from $14.8M (Q1 2026) to $16.6M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $14.9M | -10% | — |
| Q2 2026 | $16.6M | +12% | — |
| Q1 2026 | $14.8M | — | — |
Q3 2026 at a glance
Tenaya Therapeutics, Q3 2026: revenue $1.7M, net loss $18.9M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Tenaya Therapeutics' R&D spending?
Tenaya Therapeutics' R&D spending was $14.9M in Q3 2026 (third quarter 2026), -10% from Q2 2026.
How has Tenaya Therapeutics' R&D spending changed?
Over the last 3 quarters it ranged from $14.8M (Q1 2026) to $16.6M (Q2 2026).